Selected research
Industry Research
Pneumococcal 13-valent Conjugate Vaccine Industry Research Report 2026
Market perspective
The global Pneumococcal 13-valent Conjugate Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pneumococcal 13-valent Conjugate Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pneumococcal 13-valent Conjugate Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pneumococcal 13-valent Conjugate Vaccine include Pfizer, BIOKANGTAI and Walvax, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pneumococcal 13-valent Conjugate Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pneumococcal 13-valent Conjugate Vaccine Market by Company
Pfizer
BIOKANGTAI
Walvax
Pneumococcal 13-valent Conjugate Vaccine Segment by Type
0.5ml
Other
Pneumococcal 13-valent Conjugate Vaccine Segment by Application
Hospital
Clinic
Pneumococcal 13-valent Conjugate Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal 13-valent Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal 13-valent Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal 13-valent Conjugate Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pneumococcal 13-valent Conjugate Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pneumococcal 13-valent Conjugate Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pneumococcal 13-valent Conjugate Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 0.5ml
- Other
Applications
- Hospital
- Clinic
Companies covered
- Pfizer
- BIOKANGTAI
- Walvax
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size (2021-2032)
- 2.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales (2021-2032)
- 2.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Market Average Price (2021-2032)
- 2.3 Pneumococcal 13-valent Conjugate Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 0.5ml
- 2.3.3 Other
- 2.4 Pneumococcal 13-valent Conjugate Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Pneumococcal 13-valent Conjugate Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pneumococcal 13-valent Conjugate Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pneumococcal 13-valent Conjugate Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Pneumococcal 13-valent Conjugate Vaccine, Established Date
- 3.9 Global Pneumococcal 13-valent Conjugate Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer
- 4.1.1 Pfizer Company Information
- 4.1.2 Pfizer Business Overview
- 4.1.3 Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
- 4.1.5 Pfizer Recent Developments
- 4.2 BIOKANGTAI
- 4.2.1 BIOKANGTAI Company Information
- 4.2.2 BIOKANGTAI Business Overview
- 4.2.3 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
- 4.2.5 BIOKANGTAI Recent Developments
- 4.3 Walvax
- 4.3.1 Walvax Company Information
- 4.3.2 Walvax Business Overview
- 4.3.3 Walvax Pneumococcal 13-valent Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
- 4.3.5 Walvax Recent Developments
5 Global Pneumococcal 13-valent Conjugate Vaccine Market Scenario by Region
- 5.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2027-2032
- 5.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region: 2027-2032
- 5.4 North America Pneumococcal 13-valent Conjugate Vaccine Market Facts & Figures by Country
- 5.4.1 North America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pneumococcal 13-valent Conjugate Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pneumococcal 13-valent Conjugate Vaccine Market Facts & Figures by Country
- 5.7.1 South America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Pneumococcal 13-valent Conjugate Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Pneumococcal 13-valent Conjugate Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pneumococcal 13-valent Conjugate Vaccine Value Chain Analysis
- 8.1.1 Pneumococcal 13-valent Conjugate Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pneumococcal 13-valent Conjugate Vaccine Production Mode & Process
- 8.2 Pneumococcal 13-valent Conjugate Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pneumococcal 13-valent Conjugate Vaccine Distributors
- 8.2.3 Pneumococcal 13-valent Conjugate Vaccine Customers
9 Global Pneumococcal 13-valent Conjugate Vaccine Analyzing Market Dynamics
- 9.1 Pneumococcal 13-valent Conjugate Vaccine Industry Trends
- 9.2 Pneumococcal 13-valent Conjugate Vaccine Industry Drivers
- 9.3 Pneumococcal 13-valent Conjugate Vaccine Industry Opportunities and Challenges
- 9.4 Pneumococcal 13-valent Conjugate Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst